{
  "source": "PA-Notification-Tavalisse.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1253-8\nProgram Prior Authorization/Notification\nMedication Tavalisse® (fostamatinib disodium hexahydrate)\nP&T Approval Date 8/2018, 8/2019, 9/2020, 9/2021, 1/2022, 1/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nTavalisse (fostamatinib) is a kinase inhibitor indicated for the treatment of thrombocytopenia in\nadult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient\nresponse to a previous treatment.\n2. Coverage Criteriaa:\nA. Chronic immune thrombocytopenia (ITP)\n1. Initial Authorization\na. Tavalisse will be approved based on both of the following criteria\n(1) Diagnosis of chronic immune thrombocytopenia (ITP)\n-AND-\n(2) Patient has had an insufficient response to a previous treatment (e.g.,\ncorticosteroids, immunoglobulins, thrombopoietin receptor agonists, splenectomy)\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Tavalisse will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Tavalisse therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n© 2025 UnitedHealthcare Services, Inc.\n1\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Tavalisse [package insert]. South San Francisco, CA: Rigel Pharmaceuticals; November 2020.\nProgram Prior Authorization/Notification – Tavalisse (fostamatinib disodium\nhexahydrate)\nChange Control\n8/2018 New program\n8/2019 Annual review with no chang",
    " CA: Rigel Pharmaceuticals; November 2020.\nProgram Prior Authorization/Notification – Tavalisse (fostamatinib disodium\nhexahydrate)\nChange Control\n8/2018 New program\n8/2019 Annual review with no changes to clinical coverage criteria.\n9/2020 Annual review. Removed splenectomy from listing of previous treatment\nrequirements.\n9/2021 Annual review with no changes to clinical coverage criteria. Reference\nupdated.\n1/2022 Revised try/fail criteria to insufficient response.\n1/2023 Annual review with no changes to clinical coverage criteria. Added state\nmandate.\n1/2024 Annual review with no changes to clinical coverage criteria.\n1/2025 Annual review. Updated initial authorization to 12 months.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}